Prevention & care

Heart valve disease: stenosis, regurgitation, prolapse, assessment, repair or replacement, and early-intervention uncertainty

10 sources · Latest source check 2026-10-09 UTC

On this page

Heart valve disease affects one or more of the four valves that direct blood flow through the heart. A valve can narrow, leak or lack a normal opening. The affected valve, mechanism and severity matter; “a valve problem” is not a complete diagnosis or one uniform treatment category.[1]

Common valve terms describe different abnormalities

Common valve terms describe different abnormalities
Term	What it describes
Stenosis	An opening that is too narrow, restricting forward flow.[2]
Regurgitation or insufficiency	Backflow when a valve does not seal adequately.[2]
Prolapse	Valve leaflets bulge backward; this does not always produce important leakage.[2]
Atresia	No normal valve opening, usually a congenital problem.[2]
Mixed or multiple valve disease	More than one mechanism or more than one valve may be involved.[2]

Anatomy changes the consequences

The NHS distinguishes the aortic and mitral valves on the left side from the pulmonary and tricuspid valves on the right. A report should name the valve and its abnormality rather than simply say “heart disease.” Pressure, flow and associated chamber changes need clinical interpretation; a familiar symptom does not identify which valve is responsible.[4]

A leaflet finding is different from significant regurgitation

NHLBI explains that mitral valve prolapse does not necessarily cause backflow or symptoms. When significant regurgitation occurs, its consequences and progression require assessment. Likewise, a bicuspid aortic valve describes two leaflets rather than the usual three; it is an anatomical finding that can lead to narrowing, not an automatic statement that severe stenosis is already present.[2]

Congenital anatomy and acquired damage are different pathways

NHLBI describes congenital valve problems, aging-associated change and acquired contexts involving disease, medicines or procedures. Some valve findings run in families, while many do not establish a specific inherited variant. Congenital forms range widely in severity. Lifestyle risk reduction matters for general cardiovascular health but cannot be assumed to reverse every structural valve abnormality.[3]

Symptoms can be absent or overlap with other conditions

Fatigue, breathlessness, dizziness, fainting, chest discomfort and palpitations can occur. NHLBI notes that some people have no symptoms or develop them gradually. These findings are not specific to valve disease. Severity and cardiac effects may therefore require imaging even when someone feels well, rather than being judged solely by exercise confidence.[1]

New severe chest or breathing symptoms need urgent care

The NHS advises emergency assessment for severe breathing difficulty or sudden concerning chest pain, including pain accompanied by breathlessness or palpitations. Online valve information cannot distinguish these symptoms from other emergencies. Persistent but less acute symptoms also warrant clinical assessment rather than a self-diagnosis based on a murmur or fatigue alone.[4]

Echocardiography examines structure and flow

NHLBI identifies echocardiography as the main test for valve problems. Ultrasound produces moving heart images; Doppler examines blood flow. An ECG records electrical activity and answers a different question. Listening to a murmur can prompt investigation, but it does not replace imaging-based characterization of the affected valve and physiological consequences.[5]

Medicines, repair and replacement have different purposes

NHLBI describes medicines for symptoms or associated problems, and procedures to repair or replace a valve. Treating fluid buildup or blood pressure is not the same as physically rebuilding a severely damaged valve. Lifestyle care and appropriate activity support cardiovascular health, with the exercise level tailored to clinical status rather than an unrestricted training prescription.[6]

A procedure does not remove every follow-up need

NHLBI emphasizes continuing medicines and checkups after repair or replacement. The new valve or repaired structure, other heart conditions and treatment complications remain relevant. Feeling better is a meaningful outcome but not proof that monitoring, prescribed medication or future reassessment is no longer necessary.[6]

The 2025 guideline emphasizes team decisions and scope

The ESC/EACTS update emphasizes Heart Teams, specialized valve centers, patient-centered decisions and advanced imaging. Its detailed focus is acquired valve disease; congenital, aortic and overlapping conditions also have separate guidance. A general article cannot substitute one age-based rule for those differences or assume that the least invasive option is best for everyone.[7]

Mechanical and tissue valves do not have identical medication needs

The original guideline states that mechanical valves require lifelong vitamin-K-antagonist anticoagulation with INR monitoring. Direct oral anticoagulants are not a universal substitute. Biological valves and other indications have different treatment contexts. Choice of prosthesis therefore involves more than how long a device might last; monitoring, bleeding/thrombotic risks and individual circumstances matter. No personal target or interruption schedule is supplied.[7]

EARLY TAVR favored early intervention for its composite endpoint

EARLY TAVR randomized 901 predominantly older, low-surgical-risk patients with asymptomatic severe aortic stenosis to early transfemoral catheter valve replacement or surveillance. Over median 3.8 years, death, stroke or unplanned cardiovascular hospitalization occurred in 26.8% versus 45.3%: hazard ratio 0.50, 95% confidence interval 0.40–0.63. Edwards Lifesciences funded the study.[8]

The component death rates were 8.4% and 9.2%, while hospitalization differed more. During follow-up, 87% of surveillance participants underwent valve replacement. This compares timing strategies, not replacement against never receiving a procedure. Its composite advantage is not a separate proven survival advantage or evidence about every other valve lesion.[8]

EVOLVED did not show a statistically clear primary-endpoint difference

EVOLVED enrolled 224 patients with asymptomatic severe aortic stenosis and myocardial fibrosis, below the planned 356. Early surgical or catheter intervention was compared with conservative management. Death or unplanned aortic-stenosis hospitalization occurred in 18% versus 23%: hazard ratio 0.79, 95% confidence interval 0.44–1.43. The wide interval leaves substantial uncertainty; lack of a clear result is not proof of equal benefit.[9]

The 2026 guideline correction fixes a symptom-class range

The August 6, 2026 correction body changes a symptom-class range in section 9.2.4.2 from an erroneous range ending at V to the correct II–IV. It concerns intervention wording in secondary mitral regurgitation after appropriate medical/device care. The notice does not announce a new indication to intervene on every asymptomatic valve finding.[10]

Evidence & uncertainty

Assessment and treatment are established, but intervention timing depends on the particular lesion and person. Two recent trials in asymptomatic severe aortic stenosis reached different primary-endpoint results. Their populations, procedures, outcomes and precision differ; neither justifies treating every symptom-free valve finding identically.[8][9]

Selected-source overview · Independent review pending

Published questions

Are valve stenosis and regurgitation the same abnormality?

Selected-source overview · Independent review pending. Read the evidence context.

Narrowing restricts forward flow; regurgitation permits backflow.[2]

Evidence behind this answer

Heart Valve Diseases: types
agency condition or prevention explanation · 2022
Selected relevant original official page passages inspected · 2022: stenosis, regurgitation, atresia, prolapse and bicuspid/multiple-valve distinctions